ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Endo Buys Qualitest In Generics Deal

by Michael McCoy
October 4, 2010 | APPEARED IN VOLUME 88, ISSUE 40

Endo Pharmaceuticals has agreed to acquire the generic drug maker Qualitest Pharmaceuticals for $1.2 billion. Endo was formed in 1997 out of DuPont Merck’s generic drugs business. It has made several recent acquisitions, including the purchase of Indevus Pharmaceuticals and of drug delivery specialist Penwest Pharmaceuticals. Qualitest, owned by the investment firm Apax Partners, calls itself the sixth-largest generics company in the U.S. Its roughly $350 million in annual sales will increase Endo’s sales to about $2 billion.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment